Compare Quest Diagnostics Inc (DGX) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Linde PLC — how do they compare? Quest Diagnostics Inc trades at $231.14 (market cap $25.48B), while Linde PLC trades at $480.5 (market cap $222.05B). The key difference: Linde PLC is far larger — about 8.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Linde PLC for 88 Days on average.
| DGX | LIN | |
|---|---|---|
Market Cap | $25.48B | $222.05B |
Volume | 941,866 | 2,116,440 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $546.64 |
52-Week Low | $173.49 | $389.38 |
Typical Hold Time | 56 Days | 88 Days |
Enterprise Value | $31.23B | $245.17B |
Dividend Yield | 1.49% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.
The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
